US Stock MarketDetailed Quotes
IOVA Iovance Biotherapeutics
- 9.920
- +1.980+24.94%
Close Aug 9 16:00 ET
- 9.860
- -0.060-0.60%
Post 20:01 ET
3.01BMarket Cap-5940P/E (TTM)
10.160High8.660Low23.63MVolume9.390Open7.940Pre Close228.47MTurnover10.23%Turnover RatioLossP/E (Static)303.51MShares18.33052wk High3.92P/B2.29BFloat Cap3.21052wk Low--Dividend TTM231.05MShs Float165.000Historical High--Div YieldTTM18.89%Amplitude1.000Historical Low9.670Avg Price1Lot Size
Iovance Biotherapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 12,969.75%31.11M | 715K | 1.19M | 482K | 469K | 238K | 0 | 0 | 0 | 0 |
| Operating revenue | 12,969.75%31.11M | --715K | --1.19M | --482K | --469K | --238K | --0 | --0 | --0 | --0 |
| Cost of revenue | 1,430.15%31.37M | 7.26M | 10.76M | 4.37M | 4.34M | 2.05M | 0 | 0 | 0 | 0 |
| Gross profit | 85.54%-262K | -6.55M | -9.57M | -3.88M | -3.87M | -1.81M | 0 | 0 | 0 | 0 |
| Operating expense | -6.12%101.65M | 0.29%111.18M | 13.07%450.99M | 9.66%117.37M | 14.04%114.49M | 8.56%108.27M | 20.87%110.86M | 16.39%398.88M | 7.61%107.04M | 16.41%100.4M |
| Selling and administrative expenses | 80.45%39.57M | 11.63%31.39M | 2.71%106.92M | 13.00%29.9M | -3.33%26.96M | -16.72%21.93M | 20.11%28.12M | 24.42%104.1M | 10.96%26.46M | 33.54%27.89M |
| Research and development costs | -28.10%62.08M | -3.57%79.78M | 16.72%344.08M | 8.56%87.47M | 20.72%87.53M | 17.63%86.35M | 21.13%82.73M | 13.80%294.78M | 6.56%80.57M | 10.94%72.5M |
| Operating profit | 7.42%-101.91M | -6.19%-117.72M | -15.46%-460.56M | -13.29%-121.26M | -17.90%-118.36M | -10.38%-110.09M | -20.87%-110.86M | -16.39%-398.88M | -7.61%-107.04M | -16.41%-100.4M |
| Net non-operating interest income expense | 8.89%3.36M | -4.25%3.34M | 336.95%13.04M | 81.60%3.12M | 332.18%3.36M | 700.26%3.08M | 3,188.68%3.49M | 561.86%2.99M | 1,171.85%1.72M | 547.50%777K |
| Non-operating interest income | 8.89%3.36M | -4.25%3.34M | 336.95%13.04M | 81.60%3.12M | 332.18%3.36M | 700.26%3.08M | 3,188.68%3.49M | 561.86%2.99M | 1,171.85%1.72M | 547.50%777K |
| Other net income (expense) | ||||||||||
| Income before tax | 7.89%-98.56M | -6.53%-114.38M | -13.04%-447.52M | -12.17%-118.14M | -15.44%-115M | -7.71%-107.01M | -17.21%-107.37M | -15.67%-395.89M | -6.03%-105.32M | -15.67%-99.62M |
| Income tax | -205.66%-1.46M | -1.41M | -3.48M | -1.76M | -1.24M | -477K | 0 | 0 | 0 | 0 |
| Net income | 8.85%-97.1M | -5.22%-112.98M | -12.16%-444.04M | -10.50%-116.38M | -14.20%-113.76M | -7.23%-106.53M | -17.21%-107.37M | -15.67%-395.89M | -6.03%-105.32M | -15.67%-99.62M |
| Net income continuous Operations | 8.85%-97.1M | -5.22%-112.98M | -12.16%-444.04M | -10.50%-116.38M | -14.20%-113.76M | -7.23%-106.53M | -17.21%-107.37M | -15.67%-395.89M | -6.03%-105.32M | -15.67%-99.62M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 8.85%-97.1M | -5.22%-112.98M | -12.16%-444.04M | -10.50%-116.38M | -14.20%-113.76M | -7.23%-106.53M | -17.21%-107.37M | -15.67%-395.89M | -6.03%-105.32M | -15.67%-99.62M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 8.85%-97.1M | -5.22%-112.98M | -12.16%-444.04M | -10.50%-116.38M | -14.20%-113.76M | -7.23%-106.53M | -17.21%-107.37M | -15.67%-395.89M | -6.03%-105.32M | -15.67%-99.62M |
| Basic earnings per share | 27.66%-0.34 | 16.00%-0.42 | 24.10%-1.89 | 29.69%-0.45 | 26.98%-0.46 | 25.40%-0.47 | 13.79%-0.5 | -11.66%-2.49 | -1.59%-0.64 | -14.55%-0.63 |
| Diluted earnings per share | 27.66%-0.34 | 16.00%-0.42 | 24.10%-1.89 | 29.69%-0.45 | 26.98%-0.46 | 25.40%-0.47 | 13.79%-0.5 | -11.66%-2.49 | -1.59%-0.64 | -14.55%-0.63 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
